Bellevue Life Sciences Acquisition Corp. (BLAC)
$
3.01
-3.72 (-123.59%)
Key metrics
Financial statements
Free cash flow per share
-0.4861
Market cap
7 Million
Price to sales ratio
0
Debt to equity
0.1192
Current ratio
0.0101
Income quality
4.1371
Average inventory
0
ROE
-0.0200
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Bellevue Life Sciences Acquisition Corp., established in 2020 and headquartered in Bellevue, Washington, is focused on executing a business combination, which may include a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or a similar transaction with one or more entities. The company aims to make acquisitions specifically within the healthcare industry, reflecting its commitment to enhancing the sector. The company incurred an income tax expense of $540,811.00 indicating its tax obligations. The net income ratio is 0.00 reflecting the company's profitability margin, while the weighted average number of shares outstanding is 5,622,954.00 highlighting the company's shareholder base. Additionally, the net total of other income and expenses is $2,775,291.00 reflecting non-core financial activities, and the diluted EPS is $0.07 accounting for potential share dilution. The stock is affordable at $3.01 suitable for budget-conscious investors. Despite its accessibility, the stock has a low average trading volume of 15,258.00 indicating lower market activity. With a market capitalization of $6,982,448.00 the company is classified as a small-cap player in the financial markets. It is a key player in the Shell Companies industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Financial Services sector, driving innovation and growth within its respective field. As Bellevue Life Sciences Acquisition Corp. continues to pursue strategic acquisitions in the healthcare domain, it positions itself as a notable entity among small-cap companies, striving for impactful developments in their industry.
What is Bellevue Life Sciences Acquisition Corp. (BLAC)'s stock forecast?
Analysts predict Bellevue Life Sciences Acquisition Corp. stock to fluctuate between $3.01 (low) and $13.40 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Bellevue Life Sciences Acquisition Corp.'s market capitalization?
As of 2025-02-14, Bellevue Life Sciences Acquisition Corp.'s market cap is $6,982,448, based on 2,319,750 outstanding shares.
How does Bellevue Life Sciences Acquisition Corp. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Bellevue Life Sciences Acquisition Corp. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Bellevue Life Sciences Acquisition Corp. (BLAC) stock?
To buy Bellevue Life Sciences Acquisition Corp. (BLAC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BLAC. Place an order (Market, Limit, etc.).
What is the best time to invest in Bellevue Life Sciences Acquisition Corp.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Bellevue Life Sciences Acquisition Corp. perform in the last earnings report?
Revenue: $0 | EPS: $0.07 | Growth: -1,941.03%.
Where can I find Bellevue Life Sciences Acquisition Corp.'s investor relations reports?
Visit https://www.bellevuespac.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Bellevue Life Sciences Acquisition Corp.?
You can explore historical data from here
What is the all-time high and low for Bellevue Life Sciences Acquisition Corp. stock?
All-time high: $13.40 (2024-11-14) | All-time low: $3.01 (2025-02-14).
What are the key trends affecting Bellevue Life Sciences Acquisition Corp. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
4 months ago
SEOUL, South Korea , Feb. 13, 2025 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. ("BLAC") announced today the approval of each of the proposals presented at the special meeting of its stockholders (the "Special Meeting") held today, including the proposal for the business combination with OSR Holdings Co., Ltd. (the "Transaction").
prnewswire.com
a year ago
BELLEVUE, Wash. , May 13, 2024 /PRNewswire/ -- As previously announced, on May 10, 2024, Bellevue Life Sciences Acquisitions Corp. (Nasdaq: BLAC) ("BLAC") convened a special meeting of stockholders (the "Special Meeting"), adjourned the Special Meeting without any business being conducted, and announced that the Special Meeting will be reconvened at 9:00 a.m.
prnewswire.com
a year ago
SEOUL, South Korea , April 22, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical development resources and launch a strategic collaboration between the two companies. Through the MOU, the two companies will explore various ways to collaborate to create synergies between current platform technologies and new drug candidates.
prnewswire.com
2 years ago
BELLEVUE, Wash. and SEOUL, South Korea , Nov. 16, 2023 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC), a publicly traded special purpose acquisition company ("BLAC"), and OSR Holdings Co., Ltd.
prnewswire.com
2 years ago
BELLEVUE, Wash. and SEOUL, South Korea, July 11, 2023 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC), a publicly traded special purpose acquisition company ("BLAC"), and OSR Holdings, Ltd. ("OSR Holdings"), a global healthcare holding company, announced today that they have entered into an exclusive, non-binding letter of intent, with the goal of completing a business combination in the fourth quarter of 2023, resulting in OSR Holdings becoming a publicly traded company.
See all news
